The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms RAI-skip
- 04 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 08 Jun 2015 New trial record